

Brexafemme (ibrexafungerp)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Six months

Medications	Quantity Limit
Brexafemme (ibrexafungerp) 150 mg	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Brexafemme (ibrexafungerp) may be approved when the following criteria are met:

- I. Individual has a diagnosis of vulvovaginal candidiasis; **OR**
- II. Individual has a diagnosis of recurrent vulvovaginal candidiasis (three or more episodes of vulvovaginal candidiasis within the prior 12 months);

AND

- III. For treatment of vulvovaginal candidiasis, individual has had a trial and inadequate response to oral fluconazole for current episode (Pappas 2016). Medication samples/coupons/discount cards are excluded from consideration as a trial.;
OR
- IV. For recurrent vulvovaginal candidiasis, individual has had a trial and inadequate response to oral fluconazole maintenance therapy (Pappas 2016). Medication samples/coupons/discount cards are excluded from consideration as a trial.;
OR
- V. Individual has intolerance or contraindication to fluconazole.

Key References:

1. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infection Treatment Guidelines, 2021. Available at <https://www.cdc.gov/std/treatment-guidelines/toc.htm>. Accessed: January 7, 2023.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 8, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Pappas PG, Kauffman CA, Andes D, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016; 62(4):E1-50.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.